Biotricity, Inc. (BTCY)

USD 0.5

(2.04%)

Net Debt Summary of Biotricity, Inc.

Biotricity, Inc.'s latest annual net debt in 2024 was 23.09 Million USD , up 21.7% from previous year.
Biotricity, Inc.'s latest quarterly net debt in 2024 FY was 23.09 Million USD , up 21.7% from previous quarter.
Biotricity, Inc. reported annual net debt of 18.97 Million USD in 2023, up 477.32% from previous year.
Biotricity, Inc. reported annual net debt of 3.28 Million USD in 2022, up 31.18% from previous year.
Biotricity, Inc. reported quarterly net debt of 20.27 Million USD for 2024 Q1, up 6.86% from previous quarter.
Biotricity, Inc. reported quarterly net debt of 23.09 Million USD for 2024 FY, up 21.7% from previous quarter.

Annual Net Debt Chart of Biotricity, Inc. (2024 - 2014)

Historical Annual Net Debt of Biotricity, Inc. (2024 - 2014)

Year	Net Debt	Net Debt Growth
2024	23.09 Million USD	21.7%
2023	18.97 Million USD	477.32%
2022	3.28 Million USD	31.18%
2021	2.5 Million USD	80.45%
2020	1.38 Million USD	72.69%
2019	804.05 Thousand USD	195.31%
2018	-843.64 Thousand USD	-174.52%
2017	1.13 Million USD	203.37%
2016	373.17 Thousand USD	1175.3%
2015	29.26 Thousand USD	45.5%
2014	20.11 Thousand USD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q4	23.09 Million USD	2.62%
2024 Q1	20.27 Million USD	6.86%
2024 FY	23.09 Million USD	21.7%
2024 Q3	22.5 Million USD	11.39%
2024 Q2	20.2 Million USD	-0.37%
2023 Q2	12.45 Million USD	58.77%
2023 FY	18.97 Million USD	477.32%
2023 Q4	18.97 Million USD	11.01%
2023 Q3	17.09 Million USD	37.25%
2023 Q1	7.84 Million USD	138.66%
2022 Q4	3.28 Million USD	278.66%
2022 FY	3.28 Million USD	31.18%
2022 Q3	-1.83 Million USD	79.54%
2022 Q2	-8.99 Million USD	-243.54%
2022 Q1	6.26 Million USD	150.03%
2021 FY	2.5 Million USD	80.45%
2021 Q1	3.59 Million USD	159.16%
2021 Q3	4.05 Million USD	9.95%
2021 Q4	2.5 Million USD	-38.23%
2021 Q2	3.68 Million USD	2.52%
2020 Q3	227.04 Thousand USD	-94.28%
2020 Q1	2.54 Million USD	217.02%
2020 Q4	1.38 Million USD	511.58%
2020 FY	1.38 Million USD	72.69%
2020 Q2	3.96 Million USD	55.64%
2019 FY	804.05 Thousand USD	195.31%
2019 Q2	-83.25 Thousand USD	58.92%
2019 Q1	-202.65 Thousand USD	75.98%
2019 Q4	804.05 Thousand USD	10699.16%
2019 Q3	-7586.00 USD	90.89%
2018 Q2	-607.14 Thousand USD	49.1%
2018 FY	-843.64 Thousand USD	-174.52%
2018 Q4	-843.64 Thousand USD	66.01%
2018 Q3	-2.48 Million USD	-308.84%
2018 Q1	-1.19 Million USD	-205.36%
2017 FY	1.13 Million USD	203.37%
2017 Q1	1.51 Million USD	58.68%
2017 Q2	699.92 Thousand USD	-53.93%
2017 Q3	1.28 Million USD	84.03%
2017 Q4	1.13 Million USD	-12.11%
2016 Q1	46.23 Thousand USD	0.0%
2016 Q2	29.26 Thousand USD	-36.71%
2016 Q3	373.17 Thousand USD	1175.3%
2016 Q4	957.45 Thousand USD	156.57%
2016 FY	373.17 Thousand USD	1175.3%
2015 FY	29.26 Thousand USD	45.5%
2015 Q2	20.11 Thousand USD	0.0%
2014 FY	20.11 Thousand USD	0.0%

Peer Net Debt Comparison of Biotricity, Inc.

Name	Net Debt	Net Debt Difference
Acutus Medical, Inc.	12.27 Million USD	-88.067%
Cell MedX Corp.	244.05 Thousand USD	-9362.256%
Dynatronics Corporation	6.2 Million USD	-272.221%
Nemaura Medical Inc.	9.92 Million USD	-132.672%
PetVivo Holdings, Inc.	1.27 Million USD	-1707.456%
RetinalGenix Technologies Inc.	506.53 Thousand USD	-4458.969%
Sonendo, Inc.	26.34 Million USD	12.335%
Telesis Bio, Inc.	32.63 Million USD	29.239%
Talis Biomedical Corporation	-57.06 Million USD	140.468%
Viveve Medical, Inc.	-13.81 Million USD	267.181%